Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734474 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,202
- Enrollment target
NCT00734474 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,202 participants.
The verdict
NCT00734474, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,202 participants
- Enrollment target
Study Summary
This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type 2 diabetes mellitus on Metformin.
Interventions
- DRUG Metformin
- DRUG Sitagliptin
- DRUG Placebo tablet
- DRUG LY2189265
- DRUG Placebo solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,202 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00734474
The ClinicalTrials.gov registry entry for NCT00734474 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT00734474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00734474 about?
NCT00734474 is a clinical study titled "A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin". This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type 2 diabetes mellitus on Metfo...
What is the current status of trial NCT00734474?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,202 participants. The study started on 2008-08. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00734474?
The interventions under investigation include: Metformin (DRUG), Sitagliptin (DRUG), Placebo tablet (DRUG), LY2189265 (DRUG), Placebo solution (DRUG).
Who is sponsoring clinical trial NCT00734474?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.